
Shape Therapeutics is a biotechnology company focused on programmable RNA medicine, leveraging AI and RNA technology to develop safe and effective treatments for genetic disorders. Their innovative platform, which includes RNAfix® for correcting mutations and advanced delivery systems, aims to make these therapies accessible at scale. With a commitment to harnessing data-driven insights, Shape TX is positioned to lead in the RNA therapeutics market, addressing hard-to-treat diseases and improving patient outcomes.

Shape Therapeutics is a biotechnology company focused on programmable RNA medicine, leveraging AI and RNA technology to develop safe and effective treatments for genetic disorders. Their innovative platform, which includes RNAfix® for correcting mutations and advanced delivery systems, aims to make these therapies accessible at scale. With a commitment to harnessing data-driven insights, Shape TX is positioned to lead in the RNA therapeutics market, addressing hard-to-treat diseases and improving patient outcomes.
Headquarters: Seattle, WA (700 Dexter Ave N)
Focus: AI-driven programmable RNA medicines (RNA payloads, delivery, manufacturing)
Core technology: RNAfix® (ADAR-recruiting payload), engineered viral capsids, TruStable™ cell lines
Founded: 2018
Notable investors: Breton Capital Management, Decheng Capital, NEA, Cherubic Ventures
Genetic and rare diseases; neurodegenerative and metabolic disorders.
2018
Biotechnology
“Backed by venture and growth investors including Breton Capital Management, Decheng Capital, New Enterprise Associates (NEA), Cherubic Ventures”